HWAM
RETA
Hennion & Walsh Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-43,316
| Closed | -$4.42M | – | 847 |
|
|
2023
Q2 | $4.42M | Sell |
43,316
-12,888
| -23% | -$1.31M | 0.26% | 88 |
|
|
2023
Q1 | $5.11M | Sell |
56,204
-1,870
| -3% | -$170K | 0.31% | 76 |
|
|
2022
Q4 | $2.21M | Sell |
58,074
-12,710
| -18% | -$483K | 0.14% | 192 |
|
|
2022
Q3 | $1.78M | Buy |
70,784
+4,268
| +6% | +$107K | 0.12% | 209 |
|
|
2022
Q2 | $2.02M | Buy |
66,516
+18,333
| +38% | +$557K | 0.13% | 199 |
|
|
2022
Q1 | $1.58M | Buy |
48,183
+5,673
| +13% | +$186K | 0.08% | 256 |
|
|
2021
Q4 | $1.12M | Buy |
42,510
+2,725
| +7% | +$71.9K | 0.06% | 331 |
|
|
2021
Q3 | $4M | Buy |
39,785
+3,700
| +10% | +$372K | 0.21% | 128 |
|
|
2021
Q2 | $5.11M | Buy |
36,085
+375
| +1% | +$53.1K | 0.27% | 88 |
|
|
2021
Q1 | $3.56M | Buy |
+35,710
| New | +$3.56M | 0.21% | 121 |
|